GC Cell Corporation (KOSDAQ:144510)

Market Cap	356.89B +16.4%
Revenue (ttm)	165.52B -5.1%
Net Income	-272.86B
EPS	-18,158.00
Shares Out	15.03M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	31,873
Average Volume	32,148
Open	24,600
Previous Close	24,400
Day's Range	23,650 - 24,600
52-Week Range	18,210 - 28,450
Beta	0.69
RSI	45.15
Earnings Date	May 15, 2026

About GC Cell

GC Cell Corporation develops cell therapy products. It also provides cell banking, sample inspection, clinical trial, and bio logistics services. Its main product is Immuncell-LC. GC Cell Corporation has strategic agreement with Lukas Biomedical Co., Ltd. to develop Cell therapy. The company was formerly known as Green Cross Lab Cell Corporation and changed its name to GC Cell Corporation in November 2021. GC Cell Corporation was founded in 2011 and is based in Yongin-si, South Korea.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2011
• Employees: 698
• Stock Exchange: KOSDAQ
• Ticker Symbol: 144510

Financial Performance

In 2025, GC Cell's revenue was 165.52 billion, a decrease of -5.12% compared to the previous year's 174.45 billion. Losses were -272.86 billion, 269.2% more than in 2024.